Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral compounds for unmet medical needs including Influenza Virus, Coronavirus, Hepatitis C virus (“HCV”), and Norovirus infections.

Strategy Directed at Advancing Programs and Growing Value
• Advancing preclinical COVID-19 Coronavirus program leveraging patent rights and compounds recently acquired from Kansas State University Research Foundation (KSURF)
• Ongoing collaboration with Merck has accelerated influenza A/B development program
• Continue to progress our innovative pipeline for Influenza, Hep C, COVID-19 and Norovirus gastroenteritis
• Form additional strategic collaborations

Corporate Overview
Highlights
Clinical Stage Antiviral Company
Proprietary Drug Discovery Platform
Merck Influenza Collaboration

Target Diseases
Influenza
Coronavirus (COVID-19)
Hepatitis
Norovirus (Gastroenteritis)

Robust Development Pipeline

<table>
<thead>
<tr>
<th>Program</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2a</th>
<th>Phase 2b</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis C (HCV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-31244 – University of MD (Pan-genotypic NS5B NNI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC-42344 (Influenza A PB2 Inhibitor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza A/B Inhibitor</td>
<td>In collaboration with</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronavirus (COVID-19)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Replication and Protease Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norovirus (Gastroenteritis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Replication and Protease Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Management Team
Gary Wilcox, Ph.D.
Chairman and
Chief Executive Officer
Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis

Sam Lee, Ph.D.
President
Over 25 years of anti-infective drug discovery research experience and played a key role in the early development of phosphoinositide 3-kinase (PI3K) delta inhibitors

James J. Martin, MBA, CPA
Chief Financial Officer
Over 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies

Board of Directors
Gary Wilcox, Ph.D.
Chairman and
Chief Executive Officer

Roger Kornberg, Ph.D.
Director, Chief Scientist, Chairman of Scientific Advisory Board

Phillip Frost, M.D.
Director

Anthony Japour, M.D.
Director

Steve Rubin
Director

Investor Contact:
JTC
Jenene Thomas
833.475.8247
cocp@jtcir.com
Scientific Advisors

Roger Kornberg, Ph.D.
Director, Chief Scientist, Chairman of Scientific Advisory Board
Professor, Stanford University School of Medicine; Nobel Laureate

Michael Levitt, Ph.D.
Professor, Stanford University School of Medicine; Nobel Laureate

Baek Kim, Ph.D.
Director of Center for Drug Discovery, Emory University

Bob Lehman, Ph.D.
Professor (Emeritus), Stanford University School of Medicine

Gary Schoolnik, M.D.
Professor (Emeritus), Stanford University School of Medicine

Roland Strong, Ph.D.
Professor, Fred Hutchinson Cancer Research Center

Christophe Verlinde, Ph.D.
Professor (Emeritus), University of Washington

Investor Contact:
JTC
Jenene Thomas
833.475.8247
cocop@jtcir.com

Technology and Drug Discovery Platform

- Fully-optimized operations from expression through high resolution X-ray data
- Stringent quality oversight of procedures for crystal production
- High throughput X-ray data collection and computation methods
- Large-scale crystal production capabilities

COVID-19: Development of Novel Antiviral Therapies

- Potential to be effective treatment for COVID-19 (SARS-CoV-2)
- Develop COVID-19 (SARS-CoV-2) inhibitors using proprietary platform technology
- Targeting viral replication complex and protease
- Potential first-in-class therapeutic and prophylactic treatment

CC-31244: HCV Non-Nucleoside Inhibitor (NNI)

Next Generation Combination Therapy

- Potential best-in-class HCV NNI with a strong profile
- Broad spectrum, potent NS5B polymerase inhibitor
- Effective against known NNI drug resistant variants
- Liver targeting
- Ready for combination therapy clinical trials

Influenza A/B Merck Collaboration

- Broad spectrum, potent dual influenza A/B preclinical lead will be developed
  - Result of Cocystal’s drug discovery platform technology
  - Binds to highly conserved site of influenza A and B replication complex
  - Expected to be active against seasonal, pandemic and drug resistant influenza A and B strains

CC-42344: Influenza PB2 Lead

- Binds to the highly conserved m7GTP binding pocket of PB2
- Exhibits broad spectrum activity against seasonal and pandemic influenza strains
- Favorable preclinical safety profile and pharmacokinetic properties
- Multiple routes of administration (oral, inhalation, IM)

Norovirus Program

- Potential first therapy
- Potent and broad-spectrum polymerase and protease inhibitors
- Structure-based lead discovery ongoing
- Licensed potent, broad spectrum protease inhibitors from KSURF